150 related articles for article (PubMed ID: 37507280)
1. Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK.
Fornacon-Wood I; Banfill K; Ahmad S; Britten A; Carson C; Dorey N; Hatton M; Hiley C; Thippu Jayaprakash K; Jegannathen A; Kidd AC; Koh P; Panakis N; Peedell C; Peters A; Pope A; Powell C; Stilwell C; Thomas B; Toy E; Wicks K; Wood V; Yahya S; Price G; Faivre-Finn C
Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):e593-e600. PubMed ID: 37507280
[TBL] [Abstract][Full Text] [Related]
2. Changes in the Management of Patients having Radical Radiotherapy for Lung Cancer during the First Wave of the COVID-19 Pandemic in the UK.
Banfill K; Croxford W; Fornacon-Wood I; Wicks K; Ahmad S; Britten A; Carson C; Dorey N; Hatton M; Hiley C; Thippu Jayaprakash K; Jegannathen A; Koh P; Panakis N; Peedell C; Pope A; Powell C; Stilwell C; Thomas B; Toy E; Wood V; Yahya S; Zhou SY; Price G; Faivre-Finn C
Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):19-27. PubMed ID: 34763964
[TBL] [Abstract][Full Text] [Related]
3. Management of mediastinal relapse after treatment with stereotactic body radiotherapy or accelerated hypofractionated radiotherapy for stage I/II non-small-cell lung cancer.
Kilburn JM; Lester SC; Lucas JT; Soike MH; Blackstock AW; Kearns WT; Hinson WH; Miller AA; Petty WJ; Munley MT; Urbanic JJ
J Thorac Oncol; 2014 Apr; 9(4):572-6. PubMed ID: 24736084
[TBL] [Abstract][Full Text] [Related]
4. Reduced Fractionation in Lung Cancer Patients Treated with Curative-intent Radiotherapy during the COVID-19 Pandemic.
Faivre-Finn C; Fenwick JD; Franks KN; Harrow S; Hatton MQF; Hiley C; McAleese JJ; McDonald F; O'Hare J; Peedell C; Pope T; Powell C; Rulach R; Toy E
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):481-489. PubMed ID: 32405158
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
Zwitter M; Kovac V; Smrdel U; Strojan P
J Thorac Oncol; 2006 Sep; 1(7):662-6. PubMed ID: 17409933
[TBL] [Abstract][Full Text] [Related]
7. The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
Dieleman E; van der Woude L; van Os R; van Bockel L; Coremans I; van Es C; De Jaeger K; Knol HP; Kolff W; Koppe F; Pomp J; Reymen B; Schinagl D; Spoelstra F; Tissing-Tan C; van der Voort van Zyp N; van der Wel A; Wijsman R; Dielwart M; Wiegman E; Damhuis R; Belderbos J
Clin Lung Cancer; 2023 Mar; 24(2):130-136. PubMed ID: 36572596
[TBL] [Abstract][Full Text] [Related]
8. Differential Relapse Patterns for Non-small Cell Lung Cancer Subtypes Adenocarcinoma and Squamous Cell Carcinoma: Implications for Radiation Oncology.
McAleese J; Taylor A; Walls GM; Hanna GG
Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):711-719. PubMed ID: 31351746
[TBL] [Abstract][Full Text] [Related]
9. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
[TBL] [Abstract][Full Text] [Related]
10. Radiation therapy of stage I and II non-small cell lung cancer (NSCLC).
Zierhut D; Bettscheider C; Schubert K; van Kampen M; Wannenmacher M
Lung Cancer; 2001 Dec; 34 Suppl 3():S39-43. PubMed ID: 11740992
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
Phillips I; Sandhu S; Lüchtenborg M; Harden S
Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
[TBL] [Abstract][Full Text] [Related]
12. Population-based analysis of curative therapies in stage II non-small cell lung cancer: the role of radiotherapy in medically inoperable patients.
Moore S; Leung B; Wu J; Ho C
Radiat Oncol; 2020 Jan; 15(1):23. PubMed ID: 32000829
[TBL] [Abstract][Full Text] [Related]
13. Outcomes treating stage III non-small cell lung carcinoma with curative-intent radiotherapy and concurrent carboplatin-paclitaxel chemotherapy.
Trinh H; Pinkham MB; Lehman M; Zarate D; Dauth M; McGrath M; McCaffrey E; Mai GT; Horwood K
Clin Respir J; 2016 Jul; 10(4):428-34. PubMed ID: 25353367
[TBL] [Abstract][Full Text] [Related]
14. Predicting the Risk of Disease Recurrence and Death Following Curative-intent Radiotherapy for Non-small Cell Lung Cancer: The Development and Validation of Two Scoring Systems From a Large Multicentre UK Cohort.
Evison M; Barrett E; Cheng A; Mulla A; Walls G; Johnston D; McAleese J; Moore K; Hicks J; Blyth K; Denholm M; Magee L; Gilligan D; Silverman S; Hiley C; Qureshi M; Clinch H; Hatton M; Philipps L; Brown S; O'Brien M; McDonald F; Faivre-Finn C
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):145-154. PubMed ID: 32978027
[TBL] [Abstract][Full Text] [Related]
15. Alternating radiotherapy and chemotherapy for inoperable Stage III non-small-cell lung cancer: long-term results of two Phase II GOTHA trials. Groupe d'Oncologie Thoracique Alpine.
Mirimanoff RO; Moro D; Bolla M; Michel G; Brambilla C; Mermillod B; Miralbell R; Alberto P
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):487-94. PubMed ID: 9806505
[TBL] [Abstract][Full Text] [Related]
16. Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC).
Lee SW; Choi EK; Chung WK; Shin KH; Ahn SD; Kim JH; Kim SW; Suh C; Lee JS; Kim WS; Kim DS; Kim DK; Park SI; Sohn KH
Lung Cancer; 2002 Jul; 37(1):65-71. PubMed ID: 12057869
[TBL] [Abstract][Full Text] [Related]
17. Comparison of accelerated hypofractionation and stereotactic body radiotherapy for Stage 1 and node negative Stage 2 non-small cell lung cancer (NSCLC).
Lucas JT; Kuremsky JG; Soike M; Hinson WW; Kearns WT; Hampton CJ; Blackstock AW; Urbanic J
Lung Cancer; 2014 Jul; 85(1):59-65. PubMed ID: 24813936
[TBL] [Abstract][Full Text] [Related]
18. A decade of community-based outcomes of patients treated with curative radiotherapy with or without chemotherapy for non-small cell lung cancer.
Pramana A; Descallar J; Vinod SK
Asia Pac J Clin Oncol; 2016 Sep; 12(3):e357-66. PubMed ID: 25155757
[TBL] [Abstract][Full Text] [Related]
19. Survival and Toxicity of Hypofractionated Intensity Modulated Radiation Therapy in 4 Gy Fractions for Unresectable Stage III Non-Small Cell Lung Cancer.
Kong C; Zhu X; Shi M; Wang L; Chen C; Tao H; Jiang N; Yan P; Zhao L; Song X; He X
Int J Radiat Oncol Biol Phys; 2020 Jul; 107(4):710-719. PubMed ID: 32275994
[TBL] [Abstract][Full Text] [Related]
20. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
